Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method
Status:
Completed
Trial end date:
2007-01-17
Target enrollment:
Participant gender:
Summary
The safety and efficacy of L059 was evaluated in patients who completed "N165 Clinical Trial
of L059". They received L059 at a daily dose from 1,000 mg to 3,000 mg in addition to their
standard concomitant AEDs